Market Research Life Sciences Market Research Pharmaceuticals Market Research Vaccines Market Research Cancer Vaccines Market Research

Cancer Biologics Market (Drug Class: Monoclonal Antibodies (mAb), Recombinant Proteins, Cancer Growth Inhibitors, Vaccines, CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and F

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 165 Pages Transparency Market Research Pvt. Ltd. May, 2023 TNPR18030460
Best Price Guarantee
Price from $5,795
Length 165 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date May, 2023
SKU TNPR18030460

Cancer Biologics Market (Drug Class: Monoclonal Antibodies (mAb), Recombinant Proteins, Cancer Growth Inhibitors, Vaccines, CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Cancer Biologics Market – Scope of Report


TMR’s report on the global Cancer Biologics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Cancer Biologics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Cancer Biologics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Cancer Biologics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Cancer Biologics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Cancer Biologics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Cancer Biologics market.

The report delves into the competitive landscape of the global Cancer Biologics market. Key players operating in the global Cancer Biologics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Cancer Biologics market profiled in this report.

Key Questions Answered in Global Cancer Biologics Market Report
  • What is the sales/revenue generated by Cancer Biologics across all regions during the forecast period?
  • What are the opportunities in the global Cancer Biologics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cancer Biologics Market – Research Objectives and Research Approach


The comprehensive report on the global Cancer Biologics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Cancer Biologics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Cancer Biologics market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Biologics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Biologics Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Overview: Advances in Cancer Diagnostics & Therapeutics
5.3. Cancer Incidence & Prevalence Rate by Region/Key Countries
5.4. Key Product Brand Analysis
5.5. Covid-19 Impact Analysis
6. Global Cancer Biologics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Monoclonal Antibodies (mAb)
6.3.1.1. Naked mAb
6.3.1.2. Conjugated mAb
6.3.1.3. Bispecific mAb
6.3.2. Recombinants Proteins
6.3.3. Cancer Growth Inhibitors
6.3.3.1. Tyrosine Kinase Inhibitors
6.3.3.2. mTOR Inhibitors
6.3.3.3. Others (Proteasome Inhibitors)
6.3.4. Vaccines
6.3.4.1. Preventive Vaccines
6.3.4.2. Therapeutic Vaccines
6.3.5. CAR-T Cells
6.3.6. Angiogenesis Inhibitors
6.3.7. Interleukins (IL)
6.3.8. Others (Interferons (IFN), Gene Therapy, etc.)
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Cancer Biologics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Blood Cancer
7.3.2. Lung Cancer
7.3.3. Breast Cancer
7.3.4. Colorectal Cancer
7.3.5. Prostate Cancer
7.3.6. Gastric Cancer
7.3.7. Ovarian Cancer
7.3.8. Others (Skin, Liver cancer, etc.)
7.4. Market Attractiveness Analysis, by Application
8. Global Cancer Biologics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Cancer Centers
8.3.3. Academics & Research Institutes
8.4. Market Attractiveness Analysis, by End-user
9. Global Cancer Biologics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Biologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
10.2.1. Monoclonal Antibodies (mAb)
10.2.1.1. Naked mAb
10.2.1.2. Conjugated mAb
10.2.1.3. Bispecific mAb
10.2.2. Recombinants Proteins
10.2.3. Cancer Growth Inhibitors
10.2.3.1. Tyrosine Kinase Inhibitors
10.2.3.2. mTOR Inhibitors
10.2.3.3. Others (Proteasome Inhibitors)
10.2.4. Vaccines
10.2.4.1. Preventive Vaccines
10.2.4.2. Therapeutic Vaccines
10.2.5. CAR-T Cells
10.2.6. Angiogenesis Inhibitors
10.2.7. Interleukins (IL)
10.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
10.3. Market Value Forecast, by Application, 2017-2031
10.3.1. Blood Cancer
10.3.2. Lung Cancer
10.3.3. Breast Cancer
10.3.4. Colorectal Cancer
10.3.5. Prostate Cancer
10.3.6. Gastric Cancer
10.3.7. Ovarian Cancer
10.3.8. Others (Skin, Liver cancer, etc.)
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Cancer Centers
10.4.3. Academics& Research Institutes
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Cancer Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Monoclonal Antibodies (mAb)
11.2.1.1. Naked mAb
11.2.1.2. Conjugated mAb
11.2.1.3. Bispecific mAb
11.2.2. Recombinants Proteins
11.2.3. Cancer Growth Inhibitors
11.2.3.1. Tyrosine Kinase Inhibitors
11.2.3.2. mTOR Inhibitors
11.2.3.3. Others (Proteasome Inhibitors)
11.2.4. Vaccines
11.2.4.1. Preventive Vaccines
11.2.4.2. Therapeutic Vaccines
11.2.5. CAR-T Cells
11.2.6. Angiogenesis Inhibitors
11.2.7. Interleukins (IL)
11.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Blood Cancer
11.3.2. Lung Cancer
11.3.3. Breast Cancer
11.3.4. Colorectal Cancer
11.3.5. Prostate Cancer
11.3.6. Gastric Cancer
11.3.7. Ovarian Cancer
11.3.8. Others (Skin, Liver cancer, etc.)
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Cancer Centers
11.4.3. Academics& Research Institutes
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Cancer Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Monoclonal Antibodies (mAb)
12.2.1.1. Naked mAb
12.2.1.2. Conjugated mAb
12.2.1.3. Bispecific mAb
12.2.2. Recombinants Proteins
12.2.3. Cancer Growth Inhibitors
12.2.3.1. Tyrosine Kinase Inhibitors
12.2.3.2. mTOR Inhibitors
12.2.3.3. Others (Proteasome Inhibitors)
12.2.4. Vaccines
12.2.4.1. Preventive Vaccines
12.2.4.2. Therapeutic Vaccines
12.2.5. CAR-T Cells
12.2.6. Angiogenesis Inhibitors
12.2.7. Interleukins (IL)
12.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Blood Cancer
12.3.2. Lung Cancer
12.3.3. Breast Cancer
12.3.4. Colorectal Cancer
12.3.5. Prostate Cancer
12.3.6. Gastric Cancer
12.3.7. Ovarian Cancer
12.3.8. Others (Skin, Liver cancer, etc.)
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Cancer Centers
12.4.3. Academics& Research Institutes
12.5. Market Value Forecast, by Country, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Cancer Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Monoclonal Antibodies (mAb)
13.2.1.1. Naked mAb
13.2.1.2. Conjugated mAb
13.2.1.3. Bispecific mAb
13.2.2. Recombinants Proteins
13.2.3. Cancer Growth Inhibitors
13.2.3.1. Tyrosine Kinase Inhibitors
13.2.3.2. mTOR Inhibitors
13.2.3.3. Others (Proteasome Inhibitors)
13.2.4. Vaccines
13.2.4.1. Preventive Vaccines
13.2.4.2. Therapeutic Vaccines
13.2.5. CAR-T Cells
13.2.6. Angiogenesis Inhibitors
13.2.7. Interleukins (IL)
13.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Blood Cancer
13.3.2. Lung Cancer
13.3.3. Breast Cancer
13.3.4. Colorectal Cancer
13.3.5. Prostate Cancer
13.3.6. Gastric Cancer
13.3.7. Ovarian Cancer
13.3.8. Others (Skin, Liver cancer, etc.)
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Cancer Centers
13.4.3. Academics& Research Institutes
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Biologics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Monoclonal Antibodies (mAb)
14.2.1.1. Naked mAb
14.2.1.2. Conjugated mAb
14.2.1.3. Bispecific mAb
14.2.2. Recombinants Proteins
14.2.3. Cancer Growth Inhibitors
14.2.3.1. Tyrosine Kinase Inhibitors
14.2.3.2. mTOR Inhibitors
14.2.3.3. Others (Proteasome Inhibitors)
14.2.4. Vaccines
14.2.4.1. Preventive Vaccines
14.2.4.2. Therapeutic Vaccines
14.2.5. CAR-T Cells
14.2.6. Angiogenesis Inhibitors
14.2.7. Interleukins (IL)
14.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Blood Cancer
14.3.2. Lung Cancer
14.3.3. Breast Cancer
14.3.4. Colorectal Cancer
14.3.5. Prostate Cancer
14.3.6. Gastric Cancer
14.3.7. Ovarian Cancer
14.3.8. Others (Skin, Liver cancer, etc.)
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Cancer Centers
14.4.3. Academics& Research Institutes
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Amgen, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Pfizer, Inc.
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. GSK plc
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Bristol-Myers Squibb Company
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Abbott
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. AstraZeneca
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Eli Lilly and Company
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Gilead Sciences, Inc.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Johnson & Johnson Services, Inc.
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings